View ValuationStevanato Group 将来の成長Future 基準チェック /26Stevanato Group利益と収益がそれぞれ年間17%と8.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.3% 16.7%なると予測されています。主要情報17.0%収益成長率16.66%EPS成長率Life Sciences 収益成長20.2%収益成長率8.9%将来の株主資本利益率14.31%アナリストカバレッジGood最終更新日01 Jun 2026今後の成長に関する最新情報お知らせ • May 09Stevanato Group S.p.A. Maintains Earnings Guidance for the Fiscal Year 2026Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be in the range of EUR 1,260.0 million to EAR 1,290.0 million. Operating profit to be EUR 212.7 million to EUR 227.8 million. Net profit to be EUR 149.6 million to EUR 160.7 million. Diluted EPS to be EUR 0.55 to EUR 0.59.お知らせ • Mar 05Stevanato Group S.P.A. Provides Earnings Guidance for the Fiscal 2026Stevanato Group S.p.A. provided earnings guidance for the fiscal 2026. For the year, the company expected revenue in the range of €1.26 billion to €1.29 billion; Operating Profit of €212.7 million to €227.8 million; Net Profit of €149.6 million to €160.7 million; Diluted EPS of €0.55 to €0.59.お知らせ • Nov 07Stevanato Group S.P.A. Maintains Revenue Guidance for the 2025Stevanato Group S.p.A. maintained revenue guidance for the 2025. For the period, the company expects Revenue in the range of €1.160 billion to €1.190 billion.お知らせ • Aug 05Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the period, the company continues to expect revenue in the range of €1.160 billion to €1.190 billion.お知らせ • May 08Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the year, the company expects revenue in the range of €1.160 billion to €1.190 billion.お知らせ • Mar 06Stevanato Group S.p.A. Provides Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. provided earnings guidance for the fiscal year 2025. For the year, the Company expected revenue in the range of €1,160 million to €1,190 million.すべての更新を表示Recent updatesお知らせ • 20hStevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight ManagementStevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.お知らせ • Jun 05Stevanato Group S.p.A. Approves Dividend on Class A ShareStevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares.Upcoming Dividend • Jun 04Upcoming dividend of €0.054 per shareEligible shareholders must have bought the stock before 11 June 2026. Payment date: 29 July 2026. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (0.8%).Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Director Peter Soelkner was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 30Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.Declared Dividend • May 20Dividend increased to €0.054Dividend of €0.054 is 0.2% higher than last year. Ex-date: 11th June 2026 Payment date: 29th July 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.5%.お知らせ • May 12Stevanato Group S.p.A., Annual General Meeting, May 26, 2026Stevanato Group S.p.A., Annual General Meeting, May 26, 2026.お知らせ • May 09Stevanato Group S.p.A. Maintains Earnings Guidance for the Fiscal Year 2026Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be in the range of EUR 1,260.0 million to EAR 1,290.0 million. Operating profit to be EUR 212.7 million to EUR 227.8 million. Net profit to be EUR 149.6 million to EUR 160.7 million. Diluted EPS to be EUR 0.55 to EUR 0.59.お知らせ • Apr 24Stevanato Group S.p.A. to Report Q1, 2026 Results on May 07, 2026Stevanato Group S.p.A. announced that they will report Q1, 2026 results at 6:30 AM, Eastern Daylight on May 07, 2026お知らせ • Mar 05Stevanato Group S.P.A. Provides Earnings Guidance for the Fiscal 2026Stevanato Group S.p.A. provided earnings guidance for the fiscal 2026. For the year, the company expected revenue in the range of €1.26 billion to €1.29 billion; Operating Profit of €212.7 million to €227.8 million; Net Profit of €149.6 million to €160.7 million; Diluted EPS of €0.55 to €0.59.お知らせ • Feb 19Stevanato Group S.p.A. to Report Q4, 2025 Results on Mar 04, 2026Stevanato Group S.p.A. announced that they will report Q4, 2025 results at 6:30 AM, US Eastern Standard Time on Mar 04, 2026お知らせ • Nov 07Stevanato Group S.P.A. Maintains Revenue Guidance for the 2025Stevanato Group S.p.A. maintained revenue guidance for the 2025. For the period, the company expects Revenue in the range of €1.160 billion to €1.190 billion.お知らせ • Oct 22Stevanato Group S.p.A. to Report Q3, 2025 Results on Nov 06, 2025Stevanato Group S.p.A. announced that they will report Q3, 2025 results at 6:30 AM, Eastern Standard Time on Nov 06, 2025お知らせ • Aug 05Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the period, the company continues to expect revenue in the range of €1.160 billion to €1.190 billion.お知らせ • Jul 23Stevanato Group S.p.A. to Report Q2, 2025 Results on Aug 05, 2025Stevanato Group S.p.A. announced that they will report Q2, 2025 results at 6:30 AM, US Eastern Standard Time on Aug 05, 2025お知らせ • Jun 10+ 1 more updateStevanato Group S.p.A. Approves Board AppointmentsStevanato Group S.p.A. at its Ordinary Meeting of Shareholders held on May 23, 2025 approved appointment of Sue Jean Lin and Elisabetta Magistretti to its board of directors.お知らせ • May 08Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the year, the company expects revenue in the range of €1.160 billion to €1.190 billion.お知らせ • May 05Stevanato Group S.p.A., Annual General Meeting, May 23, 2025Stevanato Group S.p.A., Annual General Meeting, May 23, 2025, at 16:00 W. Europe Standard Time.お知らせ • Apr 25Stevanato Group S.p.A. to Report Q1, 2025 Results on May 08, 2025Stevanato Group S.p.A. announced that they will report Q1, 2025 results at 6:30 AM, Eastern Standard Time on May 08, 2025お知らせ • Mar 06Stevanato Group S.p.A. Provides Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. provided earnings guidance for the fiscal year 2025. For the year, the Company expected revenue in the range of €1,160 million to €1,190 million.お知らせ • Feb 25Stevanato Group S.p.A. to Report Q4, 2024 Results on Mar 06, 2025Stevanato Group S.p.A. announced that they will report Q4, 2024 results at 6:30 AM, US Eastern Standard Time on Mar 06, 2025Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: €0.11 (vs €0.14 in 3Q 2023)Third quarter 2024 results: EPS: €0.11 (down from €0.14 in 3Q 2023). Revenue: €277.9m (up 2.4% from 3Q 2023). Net income: €30.0m (down 21% from 3Q 2023). Profit margin: 11% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.Buy Or Sell Opportunity • Nov 05Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to €19.90. The fair value is estimated to be €15.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.お知らせ • Nov 05Stevanato Group S.P.A. Provides Earnings Guidance for the Full Year 2024Stevanato Group S.p.A. provided earnings guidance for the full year 2024. for the year, the company expects reported revenue of €1,090.0 million to €1,110.0 million, reported Operating Profit of €155.8 million to €161.8 million, reported Net Profit of €115.0 million to €119.4 million, reported Diluted EPS €0.42-€0.44.お知らせ • Oct 23Stevanato Group S.p.A. to Report Q3, 2024 Results on Nov 05, 2024Stevanato Group S.p.A. announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Nov 05, 2024お知らせ • Oct 01Stevanato Group S.p.A. to Introduce Its Large-Volume Vertiva 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI MilanStevanato Group S.p. A. announced the expansion of its Vertiva platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva®? easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule and biologic therapies, enabling treatment for conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain management. The Vertiva®? platform features a unique design with a single-use pod containing a pre-filled, pre-loaded cartridge, paired with a reusable, smart controller that communicates with a patented and magnetically coupled drive mechanism. The pod, securely interlocked with the controller, contains a pre-filled glass cartridge available in formats ranging from 3mL up to 10mL and is assembled at the factory for immediate use. This simplifies home-based treatment initiation, offering patients a safe and comfortable experience. A recent wearability study underscored this sentiment and revealed that Vertiva®? 10mL is generally well-accepted by patients who found it comfortable to wear. The device proved to securely adhere to the body without restricting movement, allowing patients to go about their daily activities easily. The smart controller provides the option to record patient usage data, which can be transferred via Bluetooth to digital health applications. Additionally, the two-part system allows for easy separation of the reusable controller from the disposable pod after treatment, significantly reducing the environmental impact of electronic components and enhancing the device's overall sustainability. Stevanato Group will leverage its integrated capabilities and its existing partnership with Thermo Fisher Scientific to bring Vertiva®? 10mL to market. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill®? cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services. The unparalleled combination of capabilities from two established industry providers will support pharma companies from drug development through to the final packaged product, reducing risks and accelerating time-to-market. Demonstrations of Vertiva®? 10mL will be available at CPHI in Milan (Oct 8-10) at Stevanato Group's booth, 20C1.Buy Or Sell Opportunity • Sep 24Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €17.70. The fair value is estimated to be €14.66, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €19.40, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 6.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.07 per share.Buy Or Sell Opportunity • Aug 28Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €17.80. The fair value is estimated to be €14.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.Buy Or Sell Opportunity • Aug 14Now 24% overvaluedOver the last 90 days, the stock has fallen 1.1% to €18.40. The fair value is estimated to be €14.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.076 (vs €0.13 in 2Q 2023)Second quarter 2024 results: EPS: €0.076 (down from €0.13 in 2Q 2023). Revenue: €259.6m (up 1.7% from 2Q 2023). Net income: €20.6m (down 40% from 2Q 2023). Profit margin: 7.9% (down from 13% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year.お知らせ • Aug 06Stevanato Group S.p.A. Updates Earnings Guidance for the Year 2024Stevanato Group S.p.A. updated earnings guidance for the year 2024. For the year, the company expects reported revenue to be between €1,090 million to €1,110 million. Reported operating profit to be between €162.9 million to €170.9 million. Reported net profit to be between €119.5 million to €125.5 million. Reported diluted EPS to be between €0.44 to €0.46.お知らせ • Jul 25Stevanato Group S.p.A. to Report Q2, 2024 Results on Aug 06, 2024Stevanato Group S.p.A. announced that they will report Q2, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 06, 2024Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €19.00, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 32% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.08 per share.Declared Dividend • May 31Dividend of €0.053 announcedShareholders will receive a dividend of €0.053. Ex-date: 4th June 2024 Payment date: 15th July 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%.お知らせ • May 29Stevanato Group S.P.A. Announces Chief Executive Officer ChangesStevanato Group S.P.A. announced that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company’s Board of Directors. Mr. Stevanato has held the position of Executive Chairman since 2021 and he previously served as Chief Executive Officer of Stevanato Group from 1998 to 2021. He is the driving force behind the Group’s long-term strategic vision and integrated value proposition. Mr. Stevanato is responsible for leading the Company’s global expansion over the last two decades, expanding the Company’s diversified product portfolio, establishing the Group’s science-based technology excellence centers, enhancing its research and development capabilities, and leading the Company through its initial public offering.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 24%After last week's 24% share price decline to €18.60, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €11.03 per share.お知らせ • May 10Stevanato Group S.P.A. Provides Revenue Guidance for 2024Stevanato Group S.p.A. provided revenue guidance for 2024. For the period, the company expects revenue in the range of €1,125 million to €1,155 million.Reported Earnings • May 09First quarter 2024 earnings released: EPS: €0.071 (vs €0.11 in 1Q 2023)First quarter 2024 results: EPS: €0.071 (down from €0.11 in 1Q 2023). Revenue: €236.0m (flat on 1Q 2023). Net income: €18.8m (down 34% from 1Q 2023). Profit margin: 8.0% (down from 12% in 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Apr 28Stevanato Group S.p.A. to Report Q1, 2024 Results on May 09, 2024Stevanato Group S.p.A. announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on May 09, 2024お知らせ • Apr 05Stevanato Group S.p.A. Announces the Appointment of Ugo Gay as Chief Operations OfficerStevanato Group S.p.A. announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain. Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations. Prior to joining Stevanato Group, Ugo held key leadership positions at renowned organizations, including the Biological Chemotherapy Institute of Turin and Diasorin, an Italian multinational biotechnology company. At Diasorin, Ugo served in various roles, from Sales to Industrial Operations, culminating in his tenure as CEO and General Manager of the new subsidiary Diasorin Italia S.p.A. In his new role as COO of Stevanato Group, Ugo Gay will shape and execute sourcing, planning, and manufacturing strategies to help drive the Company's growth and achieve its business goals and vision. With a keen focus on maximizing returns on investments and driving efficiencies, Ugo will oversee priority strategic projects and lead the development and management of information systems to support the Company's development and standardization of processes. Ugo Gay officially assumed his role as Chief Operations Officer on March 25, 2024, and will be based at Piombino Dese.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €29.00, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total returns to shareholders of 23% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €16.92 per share.お知らせ • Mar 22+ 1 more updateStevanato Group S.p.A. has completed a Follow-on Equity Offering in the amount of $330.2 million.Stevanato Group S.p.A. has completed a Follow-on Equity Offering in the amount of $330.2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,700,000 Price\Range: $26New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 41% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 08Full year 2023 earnings released: EPS: €0.55 (vs €0.54 in FY 2022)Full year 2023 results: EPS: €0.55 (up from €0.54 in FY 2022). Revenue: €1.09b (up 10% from FY 2022). Net income: €145.7m (up 2.0% from FY 2022). Profit margin: 13% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Europe.お知らせ • Mar 07Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year of 2024Stevanato Group S.p.A. provided revenue guidance for the full year of 2024. For the year, company expects Revenue in the range of €1,180 million to €1,210 million.Buy Or Sell Opportunity • Mar 01Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to €28.80. The fair value is estimated to be €23.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.お知らせ • Feb 23Stevanato Group S.p.A. to Report Q4, 2023 Results on Mar 07, 2024Stevanato Group S.p.A. announced that they will report Q4, 2023 results at 6:30 AM, Eastern Standard Time on Mar 07, 2024Buy Or Sell Opportunity • Jan 26Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 5.2% to €28.20. The fair value is estimated to be €23.19, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.お知らせ • Jan 24Stevanato Group S.p.A. Launches EZ-fill®? Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and CommercializationStevanato Group S.p. A. unveiled two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group's new EZ-fill®? Kit offers fast access to a customizable and versatile solution to pharma and biotech companies needing to efficiently fill small batches with high-quality injectable formulations during clinical trials or commercial phases. The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies. Injectables, comprising more than 60% of the over 21,000 drugs currently in development, of which 44% are biopharmaceuticals, require high-performance primary packaging and delivery technologies for proper storage and administration. The company’s EZ-fill® Kit builds on its existing ready-to-use platform of pre-sterilized containment solutions – vials, cartridges, and syringes – allowing customers to effectively screen different primary packaging in combination with drug products. The kit will be available as a modular box made up of glass ready-to-use drug containers and add-on components on request, shipped by courier. As a result, the platform can bring enhanced levels of quality and safety to patients across the entire drug life cycle and improve the rate at which new drugs enter the market. EZ-fill® Kit will be presented at Pharmapack and is expected to be available commercially beginning in the second quarter of 2024.お知らせ • Nov 01Stevanato Group S.P.A. Reiterates Revenue Guidance for the Full Year 2023Stevanato Group S.p.A. reiterated revenue guidance for the full year 2023. For the year, company expects Revenue in the range of €1.085 billion to €1.115 billion.Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.14 (vs €0.14 in 3Q 2022)Third quarter 2023 results: EPS: €0.14 (up from €0.14 in 3Q 2022). Revenue: €271.4m (up 11% from 3Q 2022). Net income: €37.9m (up 4.7% from 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Oct 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €25.00, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total returns to shareholders of 50% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €18.04 per share.お知らせ • Oct 18Stevanato Group S.p.A. to Report Q3, 2023 Results on Oct 31, 2023Stevanato Group S.p.A. announced that they will report Q3, 2023 results at 6:30 AM, US Eastern Standard Time on Oct 31, 2023Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €26.00, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €15.83 per share.お知らせ • Jul 29Stevanato Group S.P.A. Provides Revenue Guidance for the Year 2023Stevanato Group S.p.A. provided revenue guidance for the year 2023. For the period, the company expects revenue in the range of €1.085 billion to €1.115 billion.Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: €0.13 (vs €0.12 in 2Q 2022)Second quarter 2023 results: EPS: €0.13 (up from €0.12 in 2Q 2022). Revenue: €255.3m (up 9.0% from 2Q 2022). Net income: €34.3m (up 12% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Jul 15Stevanato Group S.p.A. to Report Q2, 2023 Results on Jul 28, 2023Stevanato Group S.p.A. announced that they will report Q2, 2023 results at 6:30 AM, US Eastern Standard Time on Jul 28, 2023お知らせ • Jun 13Stevanato Group S.p.A. Unveils Vertiva On-Body Delivery System Platform for Wide Range of Injectable Therapies and for Large Delivery Volumes (Up to 10mL)Stevanato Group S.p.A. unveiled Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies. Vertiva's unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. These two parts communicate through a patented magnetically coupled drive mechanism. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics. Vertiva's design is under development also to cover a broad range of volumes up to 10mL. In the Vertiva device the cartridge is preloaded and sealed into the pod during factory assembly allowing the patient to benefit from simplified treatment initiation. Administrations can be conducted more comfortably at home, and the connectivity options of Vertiva can be ready for digital health applications. Upon treatment, the pod and controller can be more easily separated, and the controller can be reused, thereby reducing the environmental impact of electronic components. Fully programmable to deliver micro-precision basal doses and full-content bolus injections, Vertiva is intended to be suitable for awide range of therapies, such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases. Vertiva platform can also accommodate different customizations, including primary packaging format for larger injection volumes, delivery duration, and user interface. The Vertiva brand name takes its cue from the word 'versatility' and suggests that the delivery profile is flexible, as it is programmable for basal and bolus delivery. The name also evokes ease of use for patients. Stevanato Group will leverage the recently announced collaboration with Thermo Fisher Scientific to bring Vertiva to market. The platform will be offered as an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain. The unparalleled combination of capabilities from two established industry providers can support pharma companies from drug development through to the final packaged product. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.お知らせ • Jun 08Stevanato Group S.p.A. Announces Dividend, Payable on July 17, 2023Stevanato Group S.p.A. announced that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.Reported Earnings • May 06First quarter 2023 earnings released: EPS: €0.11 (vs €0.10 in 1Q 2022)First quarter 2023 results: EPS: €0.11 (up from €0.10 in 1Q 2022). Revenue: €238.0m (up 12% from 1Q 2022). Net income: €28.3m (up 2.0% from 1Q 2022). Profit margin: 12% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • May 05Stevanato Group S.p.A. Reiterates Earnings Guidance for the Year 2023Stevanato Group S.p.A. reiterated earnings guidance for the year 2023. The Company is reiterating its fiscal year 2023 guidance and still expects: Revenue in the range of €1.085 billion to €1.115 billion, Operating Profit in the range of €199.9 million to €211.9 million, net profit in the range of €147.8 million to €156.9 million and Diluted EPS in the range of €0.56 to €0.59.Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €0.54 (vs €0.53 in FY 2021)Full year 2022 results: EPS: €0.54 (up from €0.53 in FY 2021). Revenue: €983.7m (up 17% from FY 2021). Net income: €143.0m (up 6.5% from FY 2021). Profit margin: 14% (down from 16% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 17Stevanato Group S.p.A. to Report Q4, 2022 Results on Mar 02, 2023Stevanato Group S.p.A. announced that they will report Q4, 2022 results at 6:30 AM, US Eastern Standard Time on Mar 02, 2023Reported Earnings • Nov 10Third quarter 2022 earnings released: EPS: €0.14 (vs €0.071 in 3Q 2021)Third quarter 2022 results: EPS: €0.14 (up from €0.071 in 3Q 2021). Revenue: €245.3m (up 14% from 3Q 2021). Net income: €36.3m (up 95% from 3Q 2021). Profit margin: 15% (up from 8.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 09Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year 2022Stevanato Group S.p.A. provided revenue guidance for the full year 2022. For the year, the company expected revenue in the range of €961 million to €971 million.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €13.90, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total loss to shareholders of 34% over the past year.Reported Earnings • Aug 05Second quarter 2022 earnings released: EPS: €0.12 (vs €0.14 in 2Q 2021)Second quarter 2022 results: EPS: €0.12 (down from €0.14 in 2Q 2021). Revenue: €234.2m (up 15% from 2Q 2021). Net income: €30.5m (down 11% from 2Q 2021). Profit margin: 13% (down from 17% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.3%, compared to a 13% growth forecast for the industry in Germany.お知らせ • Aug 05Stevanato Group S.P.A. Provides Revenue Guidance for 2022Stevanato Group S.p.A. provided revenue guidance for 2022. For the year the company is raising its full year guidance which assumes (1) revenue contributions from COVID-19 of approximately 10% of full year 2022 revenue, a decrease from the Company’s prior estimate in the low teens. This decrease is being offset by strong demand in the core business, (2) favorable currency effects, (3) an improved outlook in the Engineering Segment, and (4) the effects of inflation. As a result, the Company now expects: Revenue in the range of €955 million to €965 million, up from €935 million to €945 million.お知らせ • Jul 23Stevanato Group S.p.A. to Report Q2, 2022 Results on Aug 04, 2022Stevanato Group S.p.A. announced that they will report Q2, 2022 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2022お知らせ • Jun 03Stevanato Group S.p.A. Approves Dividend for the Year Ended December 31, 2021, Payable on July 13, 2022Stevanato Group S.p.A. announced at annual general meeting held on June 1, 2022, the shareholders approved distribution of dividends in the amount of EUR 0.051 for each ordinary share and class A share (net of treasury shares) for the year ended December 31, 2021. The dividend has a record date of June 14, 2022 and a dividend payment date of July 13, 2022.Reported Earnings • May 12First quarter 2022 earnings released: EPS: €0.10 (vs €0.15 in 1Q 2021)First quarter 2022 results: EPS: €0.10 (down from €0.15 in 1Q 2021). Revenue: €212.1m (up 10.0% from 1Q 2021). Net income: €27.7m (down 24% from 1Q 2021). Profit margin: 13% (down from 19% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 13% growth forecast for the industry in Germany.お知らせ • May 12+ 1 more updateStevanato Group S.P.A. Recommends Cash DividendStevanato Group S.p.A. Board of Directors recommended the approval of a cash dividend of approximately €13.5 million, subject to shareholder approval at the annual general meeting on June 1, 2022.業績と収益の成長予測DB:87N - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,535227N/A293512/31/20271,401190392831012/31/20261,27615715284103/31/20261,203141-12262N/A12/31/20251,18614011286N/A9/30/20251,170141-36236N/A6/30/20251,145135-64207N/A3/31/20251,125125-99184N/A12/31/20241,104118-158156N/A9/30/20241,094115-187122N/A6/30/20241,088123-257138N/A3/31/20241,083136-276140N/A12/31/20231,085146-337105N/A9/30/20231,057149-268155N/A6/30/20231,031147-216117N/A3/31/20231,010143-182135N/A12/31/2022984143-140103N/A9/30/2022924139-11499N/A6/30/2022893122-78121N/A3/31/2022863125-13133N/A12/31/202184413420133N/A9/30/202181812332139N/A6/30/202176112172171N/A3/31/202171810877171N/A12/31/20206627960156N/A12/31/201953739N/A43N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 87Nの予測収益成長率 (年間17% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 87Nの収益 ( 17% ) German市場 ( 17.1% ) よりも低い成長が予測されています。高成長収益: 87Nの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 87Nの収益 ( 8.9% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 87Nの収益 ( 8.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 87Nの 自己資本利益率 は、3年後には低くなると予測されています ( 14.3 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 20:21終値2026/06/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stevanato Group S.p.A. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Curtis MoilesBNP ParibasHugo SolvetBNP ParibasMichael RyskinBofA Global Research15 その他のアナリストを表示
お知らせ • May 09Stevanato Group S.p.A. Maintains Earnings Guidance for the Fiscal Year 2026Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be in the range of EUR 1,260.0 million to EAR 1,290.0 million. Operating profit to be EUR 212.7 million to EUR 227.8 million. Net profit to be EUR 149.6 million to EUR 160.7 million. Diluted EPS to be EUR 0.55 to EUR 0.59.
お知らせ • Mar 05Stevanato Group S.P.A. Provides Earnings Guidance for the Fiscal 2026Stevanato Group S.p.A. provided earnings guidance for the fiscal 2026. For the year, the company expected revenue in the range of €1.26 billion to €1.29 billion; Operating Profit of €212.7 million to €227.8 million; Net Profit of €149.6 million to €160.7 million; Diluted EPS of €0.55 to €0.59.
お知らせ • Nov 07Stevanato Group S.P.A. Maintains Revenue Guidance for the 2025Stevanato Group S.p.A. maintained revenue guidance for the 2025. For the period, the company expects Revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • Aug 05Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the period, the company continues to expect revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • May 08Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the year, the company expects revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • Mar 06Stevanato Group S.p.A. Provides Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. provided earnings guidance for the fiscal year 2025. For the year, the Company expected revenue in the range of €1,160 million to €1,190 million.
お知らせ • 20hStevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight ManagementStevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.
お知らせ • Jun 05Stevanato Group S.p.A. Approves Dividend on Class A ShareStevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares.
Upcoming Dividend • Jun 04Upcoming dividend of €0.054 per shareEligible shareholders must have bought the stock before 11 June 2026. Payment date: 29 July 2026. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (0.8%).
Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Director Peter Soelkner was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 30Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.
Declared Dividend • May 20Dividend increased to €0.054Dividend of €0.054 is 0.2% higher than last year. Ex-date: 11th June 2026 Payment date: 29th July 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.5%.
お知らせ • May 12Stevanato Group S.p.A., Annual General Meeting, May 26, 2026Stevanato Group S.p.A., Annual General Meeting, May 26, 2026.
お知らせ • May 09Stevanato Group S.p.A. Maintains Earnings Guidance for the Fiscal Year 2026Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be in the range of EUR 1,260.0 million to EAR 1,290.0 million. Operating profit to be EUR 212.7 million to EUR 227.8 million. Net profit to be EUR 149.6 million to EUR 160.7 million. Diluted EPS to be EUR 0.55 to EUR 0.59.
お知らせ • Apr 24Stevanato Group S.p.A. to Report Q1, 2026 Results on May 07, 2026Stevanato Group S.p.A. announced that they will report Q1, 2026 results at 6:30 AM, Eastern Daylight on May 07, 2026
お知らせ • Mar 05Stevanato Group S.P.A. Provides Earnings Guidance for the Fiscal 2026Stevanato Group S.p.A. provided earnings guidance for the fiscal 2026. For the year, the company expected revenue in the range of €1.26 billion to €1.29 billion; Operating Profit of €212.7 million to €227.8 million; Net Profit of €149.6 million to €160.7 million; Diluted EPS of €0.55 to €0.59.
お知らせ • Feb 19Stevanato Group S.p.A. to Report Q4, 2025 Results on Mar 04, 2026Stevanato Group S.p.A. announced that they will report Q4, 2025 results at 6:30 AM, US Eastern Standard Time on Mar 04, 2026
お知らせ • Nov 07Stevanato Group S.P.A. Maintains Revenue Guidance for the 2025Stevanato Group S.p.A. maintained revenue guidance for the 2025. For the period, the company expects Revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • Oct 22Stevanato Group S.p.A. to Report Q3, 2025 Results on Nov 06, 2025Stevanato Group S.p.A. announced that they will report Q3, 2025 results at 6:30 AM, Eastern Standard Time on Nov 06, 2025
お知らせ • Aug 05Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the period, the company continues to expect revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • Jul 23Stevanato Group S.p.A. to Report Q2, 2025 Results on Aug 05, 2025Stevanato Group S.p.A. announced that they will report Q2, 2025 results at 6:30 AM, US Eastern Standard Time on Aug 05, 2025
お知らせ • Jun 10+ 1 more updateStevanato Group S.p.A. Approves Board AppointmentsStevanato Group S.p.A. at its Ordinary Meeting of Shareholders held on May 23, 2025 approved appointment of Sue Jean Lin and Elisabetta Magistretti to its board of directors.
お知らせ • May 08Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the year, the company expects revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • May 05Stevanato Group S.p.A., Annual General Meeting, May 23, 2025Stevanato Group S.p.A., Annual General Meeting, May 23, 2025, at 16:00 W. Europe Standard Time.
お知らせ • Apr 25Stevanato Group S.p.A. to Report Q1, 2025 Results on May 08, 2025Stevanato Group S.p.A. announced that they will report Q1, 2025 results at 6:30 AM, Eastern Standard Time on May 08, 2025
お知らせ • Mar 06Stevanato Group S.p.A. Provides Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. provided earnings guidance for the fiscal year 2025. For the year, the Company expected revenue in the range of €1,160 million to €1,190 million.
お知らせ • Feb 25Stevanato Group S.p.A. to Report Q4, 2024 Results on Mar 06, 2025Stevanato Group S.p.A. announced that they will report Q4, 2024 results at 6:30 AM, US Eastern Standard Time on Mar 06, 2025
Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: €0.11 (vs €0.14 in 3Q 2023)Third quarter 2024 results: EPS: €0.11 (down from €0.14 in 3Q 2023). Revenue: €277.9m (up 2.4% from 3Q 2023). Net income: €30.0m (down 21% from 3Q 2023). Profit margin: 11% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.
Buy Or Sell Opportunity • Nov 05Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to €19.90. The fair value is estimated to be €15.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
お知らせ • Nov 05Stevanato Group S.P.A. Provides Earnings Guidance for the Full Year 2024Stevanato Group S.p.A. provided earnings guidance for the full year 2024. for the year, the company expects reported revenue of €1,090.0 million to €1,110.0 million, reported Operating Profit of €155.8 million to €161.8 million, reported Net Profit of €115.0 million to €119.4 million, reported Diluted EPS €0.42-€0.44.
お知らせ • Oct 23Stevanato Group S.p.A. to Report Q3, 2024 Results on Nov 05, 2024Stevanato Group S.p.A. announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Nov 05, 2024
お知らせ • Oct 01Stevanato Group S.p.A. to Introduce Its Large-Volume Vertiva 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI MilanStevanato Group S.p. A. announced the expansion of its Vertiva platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva®? easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule and biologic therapies, enabling treatment for conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain management. The Vertiva®? platform features a unique design with a single-use pod containing a pre-filled, pre-loaded cartridge, paired with a reusable, smart controller that communicates with a patented and magnetically coupled drive mechanism. The pod, securely interlocked with the controller, contains a pre-filled glass cartridge available in formats ranging from 3mL up to 10mL and is assembled at the factory for immediate use. This simplifies home-based treatment initiation, offering patients a safe and comfortable experience. A recent wearability study underscored this sentiment and revealed that Vertiva®? 10mL is generally well-accepted by patients who found it comfortable to wear. The device proved to securely adhere to the body without restricting movement, allowing patients to go about their daily activities easily. The smart controller provides the option to record patient usage data, which can be transferred via Bluetooth to digital health applications. Additionally, the two-part system allows for easy separation of the reusable controller from the disposable pod after treatment, significantly reducing the environmental impact of electronic components and enhancing the device's overall sustainability. Stevanato Group will leverage its integrated capabilities and its existing partnership with Thermo Fisher Scientific to bring Vertiva®? 10mL to market. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill®? cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services. The unparalleled combination of capabilities from two established industry providers will support pharma companies from drug development through to the final packaged product, reducing risks and accelerating time-to-market. Demonstrations of Vertiva®? 10mL will be available at CPHI in Milan (Oct 8-10) at Stevanato Group's booth, 20C1.
Buy Or Sell Opportunity • Sep 24Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €17.70. The fair value is estimated to be €14.66, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €19.40, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 6.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.07 per share.
Buy Or Sell Opportunity • Aug 28Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at €17.80. The fair value is estimated to be €14.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.
Buy Or Sell Opportunity • Aug 14Now 24% overvaluedOver the last 90 days, the stock has fallen 1.1% to €18.40. The fair value is estimated to be €14.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 18% per annum over the same time period.
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.076 (vs €0.13 in 2Q 2023)Second quarter 2024 results: EPS: €0.076 (down from €0.13 in 2Q 2023). Revenue: €259.6m (up 1.7% from 2Q 2023). Net income: €20.6m (down 40% from 2Q 2023). Profit margin: 7.9% (down from 13% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year.
お知らせ • Aug 06Stevanato Group S.p.A. Updates Earnings Guidance for the Year 2024Stevanato Group S.p.A. updated earnings guidance for the year 2024. For the year, the company expects reported revenue to be between €1,090 million to €1,110 million. Reported operating profit to be between €162.9 million to €170.9 million. Reported net profit to be between €119.5 million to €125.5 million. Reported diluted EPS to be between €0.44 to €0.46.
お知らせ • Jul 25Stevanato Group S.p.A. to Report Q2, 2024 Results on Aug 06, 2024Stevanato Group S.p.A. announced that they will report Q2, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 06, 2024
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €19.00, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 32% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.08 per share.
Declared Dividend • May 31Dividend of €0.053 announcedShareholders will receive a dividend of €0.053. Ex-date: 4th June 2024 Payment date: 15th July 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%.
お知らせ • May 29Stevanato Group S.P.A. Announces Chief Executive Officer ChangesStevanato Group S.P.A. announced that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company’s Board of Directors. Mr. Stevanato has held the position of Executive Chairman since 2021 and he previously served as Chief Executive Officer of Stevanato Group from 1998 to 2021. He is the driving force behind the Group’s long-term strategic vision and integrated value proposition. Mr. Stevanato is responsible for leading the Company’s global expansion over the last two decades, expanding the Company’s diversified product portfolio, establishing the Group’s science-based technology excellence centers, enhancing its research and development capabilities, and leading the Company through its initial public offering.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 24%After last week's 24% share price decline to €18.60, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €11.03 per share.
お知らせ • May 10Stevanato Group S.P.A. Provides Revenue Guidance for 2024Stevanato Group S.p.A. provided revenue guidance for 2024. For the period, the company expects revenue in the range of €1,125 million to €1,155 million.
Reported Earnings • May 09First quarter 2024 earnings released: EPS: €0.071 (vs €0.11 in 1Q 2023)First quarter 2024 results: EPS: €0.071 (down from €0.11 in 1Q 2023). Revenue: €236.0m (flat on 1Q 2023). Net income: €18.8m (down 34% from 1Q 2023). Profit margin: 8.0% (down from 12% in 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Apr 28Stevanato Group S.p.A. to Report Q1, 2024 Results on May 09, 2024Stevanato Group S.p.A. announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on May 09, 2024
お知らせ • Apr 05Stevanato Group S.p.A. Announces the Appointment of Ugo Gay as Chief Operations OfficerStevanato Group S.p.A. announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain. Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations. Prior to joining Stevanato Group, Ugo held key leadership positions at renowned organizations, including the Biological Chemotherapy Institute of Turin and Diasorin, an Italian multinational biotechnology company. At Diasorin, Ugo served in various roles, from Sales to Industrial Operations, culminating in his tenure as CEO and General Manager of the new subsidiary Diasorin Italia S.p.A. In his new role as COO of Stevanato Group, Ugo Gay will shape and execute sourcing, planning, and manufacturing strategies to help drive the Company's growth and achieve its business goals and vision. With a keen focus on maximizing returns on investments and driving efficiencies, Ugo will oversee priority strategic projects and lead the development and management of information systems to support the Company's development and standardization of processes. Ugo Gay officially assumed his role as Chief Operations Officer on March 25, 2024, and will be based at Piombino Dese.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €29.00, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total returns to shareholders of 23% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €16.92 per share.
お知らせ • Mar 22+ 1 more updateStevanato Group S.p.A. has completed a Follow-on Equity Offering in the amount of $330.2 million.Stevanato Group S.p.A. has completed a Follow-on Equity Offering in the amount of $330.2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,700,000 Price\Range: $26
New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 41% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 08Full year 2023 earnings released: EPS: €0.55 (vs €0.54 in FY 2022)Full year 2023 results: EPS: €0.55 (up from €0.54 in FY 2022). Revenue: €1.09b (up 10% from FY 2022). Net income: €145.7m (up 2.0% from FY 2022). Profit margin: 13% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Europe.
お知らせ • Mar 07Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year of 2024Stevanato Group S.p.A. provided revenue guidance for the full year of 2024. For the year, company expects Revenue in the range of €1,180 million to €1,210 million.
Buy Or Sell Opportunity • Mar 01Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to €28.80. The fair value is estimated to be €23.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.
お知らせ • Feb 23Stevanato Group S.p.A. to Report Q4, 2023 Results on Mar 07, 2024Stevanato Group S.p.A. announced that they will report Q4, 2023 results at 6:30 AM, Eastern Standard Time on Mar 07, 2024
Buy Or Sell Opportunity • Jan 26Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 5.2% to €28.20. The fair value is estimated to be €23.19, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.
お知らせ • Jan 24Stevanato Group S.p.A. Launches EZ-fill®? Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and CommercializationStevanato Group S.p. A. unveiled two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group's new EZ-fill®? Kit offers fast access to a customizable and versatile solution to pharma and biotech companies needing to efficiently fill small batches with high-quality injectable formulations during clinical trials or commercial phases. The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies. Injectables, comprising more than 60% of the over 21,000 drugs currently in development, of which 44% are biopharmaceuticals, require high-performance primary packaging and delivery technologies for proper storage and administration. The company’s EZ-fill® Kit builds on its existing ready-to-use platform of pre-sterilized containment solutions – vials, cartridges, and syringes – allowing customers to effectively screen different primary packaging in combination with drug products. The kit will be available as a modular box made up of glass ready-to-use drug containers and add-on components on request, shipped by courier. As a result, the platform can bring enhanced levels of quality and safety to patients across the entire drug life cycle and improve the rate at which new drugs enter the market. EZ-fill® Kit will be presented at Pharmapack and is expected to be available commercially beginning in the second quarter of 2024.
お知らせ • Nov 01Stevanato Group S.P.A. Reiterates Revenue Guidance for the Full Year 2023Stevanato Group S.p.A. reiterated revenue guidance for the full year 2023. For the year, company expects Revenue in the range of €1.085 billion to €1.115 billion.
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.14 (vs €0.14 in 3Q 2022)Third quarter 2023 results: EPS: €0.14 (up from €0.14 in 3Q 2022). Revenue: €271.4m (up 11% from 3Q 2022). Net income: €37.9m (up 4.7% from 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Oct 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €25.00, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total returns to shareholders of 50% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €18.04 per share.
お知らせ • Oct 18Stevanato Group S.p.A. to Report Q3, 2023 Results on Oct 31, 2023Stevanato Group S.p.A. announced that they will report Q3, 2023 results at 6:30 AM, US Eastern Standard Time on Oct 31, 2023
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €26.00, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €15.83 per share.
お知らせ • Jul 29Stevanato Group S.P.A. Provides Revenue Guidance for the Year 2023Stevanato Group S.p.A. provided revenue guidance for the year 2023. For the period, the company expects revenue in the range of €1.085 billion to €1.115 billion.
Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: €0.13 (vs €0.12 in 2Q 2022)Second quarter 2023 results: EPS: €0.13 (up from €0.12 in 2Q 2022). Revenue: €255.3m (up 9.0% from 2Q 2022). Net income: €34.3m (up 12% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Jul 15Stevanato Group S.p.A. to Report Q2, 2023 Results on Jul 28, 2023Stevanato Group S.p.A. announced that they will report Q2, 2023 results at 6:30 AM, US Eastern Standard Time on Jul 28, 2023
お知らせ • Jun 13Stevanato Group S.p.A. Unveils Vertiva On-Body Delivery System Platform for Wide Range of Injectable Therapies and for Large Delivery Volumes (Up to 10mL)Stevanato Group S.p.A. unveiled Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies. Vertiva's unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. These two parts communicate through a patented magnetically coupled drive mechanism. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics. Vertiva's design is under development also to cover a broad range of volumes up to 10mL. In the Vertiva device the cartridge is preloaded and sealed into the pod during factory assembly allowing the patient to benefit from simplified treatment initiation. Administrations can be conducted more comfortably at home, and the connectivity options of Vertiva can be ready for digital health applications. Upon treatment, the pod and controller can be more easily separated, and the controller can be reused, thereby reducing the environmental impact of electronic components. Fully programmable to deliver micro-precision basal doses and full-content bolus injections, Vertiva is intended to be suitable for awide range of therapies, such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases. Vertiva platform can also accommodate different customizations, including primary packaging format for larger injection volumes, delivery duration, and user interface. The Vertiva brand name takes its cue from the word 'versatility' and suggests that the delivery profile is flexible, as it is programmable for basal and bolus delivery. The name also evokes ease of use for patients. Stevanato Group will leverage the recently announced collaboration with Thermo Fisher Scientific to bring Vertiva to market. The platform will be offered as an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain. The unparalleled combination of capabilities from two established industry providers can support pharma companies from drug development through to the final packaged product. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.
お知らせ • Jun 08Stevanato Group S.p.A. Announces Dividend, Payable on July 17, 2023Stevanato Group S.p.A. announced that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.
Reported Earnings • May 06First quarter 2023 earnings released: EPS: €0.11 (vs €0.10 in 1Q 2022)First quarter 2023 results: EPS: €0.11 (up from €0.10 in 1Q 2022). Revenue: €238.0m (up 12% from 1Q 2022). Net income: €28.3m (up 2.0% from 1Q 2022). Profit margin: 12% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 05Stevanato Group S.p.A. Reiterates Earnings Guidance for the Year 2023Stevanato Group S.p.A. reiterated earnings guidance for the year 2023. The Company is reiterating its fiscal year 2023 guidance and still expects: Revenue in the range of €1.085 billion to €1.115 billion, Operating Profit in the range of €199.9 million to €211.9 million, net profit in the range of €147.8 million to €156.9 million and Diluted EPS in the range of €0.56 to €0.59.
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €0.54 (vs €0.53 in FY 2021)Full year 2022 results: EPS: €0.54 (up from €0.53 in FY 2021). Revenue: €983.7m (up 17% from FY 2021). Net income: €143.0m (up 6.5% from FY 2021). Profit margin: 14% (down from 16% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 17Stevanato Group S.p.A. to Report Q4, 2022 Results on Mar 02, 2023Stevanato Group S.p.A. announced that they will report Q4, 2022 results at 6:30 AM, US Eastern Standard Time on Mar 02, 2023
Reported Earnings • Nov 10Third quarter 2022 earnings released: EPS: €0.14 (vs €0.071 in 3Q 2021)Third quarter 2022 results: EPS: €0.14 (up from €0.071 in 3Q 2021). Revenue: €245.3m (up 14% from 3Q 2021). Net income: €36.3m (up 95% from 3Q 2021). Profit margin: 15% (up from 8.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 09Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year 2022Stevanato Group S.p.A. provided revenue guidance for the full year 2022. For the year, the company expected revenue in the range of €961 million to €971 million.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €13.90, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total loss to shareholders of 34% over the past year.
Reported Earnings • Aug 05Second quarter 2022 earnings released: EPS: €0.12 (vs €0.14 in 2Q 2021)Second quarter 2022 results: EPS: €0.12 (down from €0.14 in 2Q 2021). Revenue: €234.2m (up 15% from 2Q 2021). Net income: €30.5m (down 11% from 2Q 2021). Profit margin: 13% (down from 17% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.3%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • Aug 05Stevanato Group S.P.A. Provides Revenue Guidance for 2022Stevanato Group S.p.A. provided revenue guidance for 2022. For the year the company is raising its full year guidance which assumes (1) revenue contributions from COVID-19 of approximately 10% of full year 2022 revenue, a decrease from the Company’s prior estimate in the low teens. This decrease is being offset by strong demand in the core business, (2) favorable currency effects, (3) an improved outlook in the Engineering Segment, and (4) the effects of inflation. As a result, the Company now expects: Revenue in the range of €955 million to €965 million, up from €935 million to €945 million.
お知らせ • Jul 23Stevanato Group S.p.A. to Report Q2, 2022 Results on Aug 04, 2022Stevanato Group S.p.A. announced that they will report Q2, 2022 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2022
お知らせ • Jun 03Stevanato Group S.p.A. Approves Dividend for the Year Ended December 31, 2021, Payable on July 13, 2022Stevanato Group S.p.A. announced at annual general meeting held on June 1, 2022, the shareholders approved distribution of dividends in the amount of EUR 0.051 for each ordinary share and class A share (net of treasury shares) for the year ended December 31, 2021. The dividend has a record date of June 14, 2022 and a dividend payment date of July 13, 2022.
Reported Earnings • May 12First quarter 2022 earnings released: EPS: €0.10 (vs €0.15 in 1Q 2021)First quarter 2022 results: EPS: €0.10 (down from €0.15 in 1Q 2021). Revenue: €212.1m (up 10.0% from 1Q 2021). Net income: €27.7m (down 24% from 1Q 2021). Profit margin: 13% (down from 19% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • May 12+ 1 more updateStevanato Group S.P.A. Recommends Cash DividendStevanato Group S.p.A. Board of Directors recommended the approval of a cash dividend of approximately €13.5 million, subject to shareholder approval at the annual general meeting on June 1, 2022.